Disease Spotlight: Prostate Cancer

For patients with recurrent prostate cancer, PET scanning with 18F-flotufolastat led to major changes in treatment for 80 percent of patients and 75 percent of patients with a changed treatment focus to watchful waiting had negative scans, according to new research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).

Researchers found that a positive target of MRI led to a threefold increased risk for Gleason Grading Group (GGG) upgrading after radical prostatectomy in patients with low prostate cancer risk.

The use of actinium-225 PSMA radioligand therapy led to PSA level decreases of at least 50 percent in 57 percent of patients and a median progression-free survival rate of 7.9 months in patients with metastatic castration-resistant prostate cancer (mCRPC), according to newly published research.

A model that combines multiparametric MRI findings with clinical factors may enhance the accuracy of predicting clinically significant prostate cancer and significantly reduce unnecessary systematic prostate biopsies in biopsy-naïve patients.

Catch up on the most well-viewed prostate imaging content from 2023.

Catch up on the top AI-related news and research in radiology over the past month.

The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.

Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.

Catch up on the top radiology content of the past week.

Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.

Catch up on the top radiology content of the past week.

In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.

Catch up on the top radiology content of the past week.

Fifty-seven percent of patients with prostate cancer diagnosed with osseous metastases on bone scans had negative findings on PSMA PET imaging, according to findings from an international multicenter comparative study.

Catch up on the top radiology content of the past week.

The Current Procedural Terminology (CPT) Category III code for the Unfold AI prostate cancer mapping platform can be utilized by radiologists starting in July 2024.

Catch up on the top radiology content of the past week.

Emerging research findings suggest that a longer prostatic urethral length on MRI is associated with a 70 percent increased risk of grade >2 acute urinary toxicity after radiotherapy for prostate cancer.

Catch up on the top radiology content of the past week.

In a study of 355 multiparametric prostate MRI exams from a total of 71 scanners from 41 facilities in 18 countries, researchers found that only 23 scanners achieved a PI-QUAL score of 5 for optimal image quality.

In a recently published literature review, researchers examined the potential impact of advanced sequences, scanners, patient preparation and AI on image quality for prostate MRI exams.

Catch up on the top radiology news of the past week.

In a recent video interview, Ashesh Jani, M.D., discussed a subset analysis from the SPOTLIGHT trial that examined the utility of the PET PSMA agent flotufolastat F 18 (Posluma) for detecting prostate cancer recurrence in men with low PSA levels lower than 1 ng/mL.

Catch up on the top radiology news of the past week.

The transitional pass-through payment reimbursement code for the FDA-approved PSMA PET agent for prostate cancer detection will be effective as of October 1, according to the Centers for Medicare and Medicare Services (CMS).

For patients who had previous radiotherapy for prostate cancer (PCa), researchers found that a biparametric MRI-based deep learning model demonstrated an 81.5 percent sensitivity rate for PCa recurrence in patients previously treated with external beam radiation treatment (EBRT) and 100 percent sensitivity in patients with greater than 34 ml in gland volumes.

Catch up on the top radiology news of the past week.

In a study of over 300 patients, researchers saw no significant differences in upgrading or downgrading of prostate cancer assessment on MRI with PI-RADS 2.1 in comparison to PI-RADS 2.0

Catch up on the top radiology content of the past week.

For men with PSA scores between 4 to 10 ng/mL, a multivariate prediction model that incorporates 68Ga-PSMA PET/CT had a 92.7 AUC for predicting clinically significant prostate cancer, according to newly published research.